Product development

Citryll, is taking a new approach to treat autoimmune and other human diseases like lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis, by targeting and inhibiting the source of auto-antigens and neutrophil extracellular trap (NET) derived toxic molecules instead of broadly targeting inflammation or acquired immunity. The latter are the MoAs of the current medicines like anti-TNF antibodies, small molecule Jak inhibitors and antagonists of B cell biology like anti-CD20 antibodies.

Citryll’s lead programme, targets the formation of neutrophil extracellular traps, called NETs and its pathological consequences.

Citryll BV is a private pharmaceutical company that is dedicated to the development and commercialization of therapeutics that target NETosis and NETs. Citryll was founded by ModiQuest B.V., originator of the tACPA patents, Helmuth van Es, CEO Citryll (co-founder of Audion Therapeutics, Galapagos, Antabio and Effecta Pharma), and Renato Chirivi, CSO Citryll and co-inventor of tACPA antibodies.


Area of work

Drug discovery, Drug development

“Targeting the pathobiology of neutrophil extracellular traps”

News from Citryll

Industry veterans Paul Peter Tak and Eric Meldrum join Citryll’s Board

22 Jul 20

Citryll completes € 18.5 M fundraise to develop CIT-013, an antibody targeting Neutrophil Extracellular Traps

02 Jul 20

Citryll’s landmark paper published in Nature’s journal

26 Mar 20